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Abstract: Renal cell cancer has been refractory to drug therapy in the large majority of patients. 
Targeted agents including sunitinib have been intensively evaluated in renal cell cancer over 
the past 5 years. Sunitinib is an oral small molecule inhibitor of several targets including mul-
tiple tyrosine kinase receptors of the angiogenesis pathway. This review surveys the rationale, 
development, validation, and clinical use of sunitinib that received conditional approval for use 
in North America and Europe in 2006. In patients with the clear-cell subtype of renal cell cancer 
and metastatic disease with good or moderate prognostic factors for survival, sunitinib 50 mg 
for 4 weeks of a 6-week cycle provides superior surrogate and patient-reported outcomes when 
compared with interferon-alfa, the previous commonly used ﬁ  rst-line drug. Overall survival 
has not yet shown improvement over interferon and is problematic because of patient crossover 
from the control arm to sunitinib at disease progression. Toxicity is signiﬁ  cant but manageable 
with experienced monitoring. Sunitinib therapy is an important step forward for this condition. 
High cost and limited efﬁ  cacy support the ongoing search for further improved therapy.
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Introduction
The systemic therapy of advanced renal cell cancer is undergoing rapid transformation 
as a result of the introduction of targeted agents into the clinic. Sunitinib (Sutent®, 
Pﬁ  zer), an oral anti-angiogenesis agent, is currently becoming the ﬁ  rst-line standard 
of care for renal cancer of the clear cell type. The recent approval of sunitinib along 
with sorafenib for renal cell cancer represents the culmination of what is destined to 
become a classic example of translational research (Chow and Eckhardt 2007). The 
stepwise study of sunitinib is presented here to illustrate this logical path to progress. 
A systematic review of phase III trials was used as a basis for this work (Coppin et al 
2008), supplemented by focussed literature search using sunitinib and renal cell cancer 
as search terms in databases Medline, EMBase, clinicaltrials.gov, and controlled-trials.
com (as of July 2007).
Relevant cell biology
Angiogenesis, the generation of new blood vessels required for normal and abnormal 
tissue growth, has been a slowly developing conceptual target for cancer treatment 
(Kerbel and Folkman 2002). A clue that assisted the unraveling of the angiogenesis 
signaling pathway came from investigation of the familial Von Hippel Lindau (VHL) 
syndrome, a rare dominant inherited condition that includes development of renal cell 
carcinomas. The gene responsible for VHL syndrome, now known as the VHL tumor-
suppressor gene, was located on the short arm of chromosome 3 and subsequently 
cloned for functional analysis. In well-oxygenated conditions, the VHL gene product 
pVHL recognizes HIF1α (hypoxia inducible factor-1α) and targets it for destruction 
via ubiquitination (Rini and Small 2005). Under hypoxic conditions, HIF1α undergoes 
a conformational change, is not recognized by pVHL, and enters the cell nucleus. This 
event triggers a complex adaptive response including transcription of angiogenesis-
stimulating factors VEGF (vascular endothelial growth factor) directed to receptors on Biologics: Targets & Therapy 2008:2(1) 98
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microvascular endothelial cells and PDGF (platelet-derived 
growth factor) directed to microvascular supporting pericytes. 
In VHL syndrome, loss or mutation of the second VHL gene 
copy in renal tissue results in the angiogenesis pathway being 
constitutively active, and this second hit appears to under-
lie the pathogenesis of renal and other vascular tumors. A 
further critical breakthrough came with the recognition that 
the majority of ordinary sporadic renal cancers of the clear 
cell type are also associated with loss or dysfunction of both 
VHL gene copies (Na et al 2003), and therefore that clear cell 
renal cancer might be especially vulnerable to anti-angiogenic 
therapy. As supportive evidence, VEGF expression is 
exceptionally high in renal cancers (Escudier et al 2007b). 
Anti-angiogenic agents may attack blood vessel development 
directly at the site of normal microvascular endothelial cells 
and pericytes, an approach that might avoid the emergence 
of drug resistance resulting from genomic instability (Kerbel 
and Folkman 2002), and sunitinib is presumed to act at this 
location. Drugs may also act indirectly by antibody binding of 
elevated levels of extracellular angiogenic growth factors eg, 
bevacizumab (Avastin®, Genentech), acting on overexpressed 
receptors on tumor cells themselves eg, sunitinib, sorafenib 
(Nexavar®, Bayer) or by inhibiting related pathways such as 
mTOR upregulation of VEGF and HIF1α eg, temsirolimus 
(Torisel®, Wyeth).
Development and action of sunitinib
Sunitinib is an inhibitor of multiple members of the 
split-domain family of receptor tyrosine kinases (RTKs) 
especially those related to angiogenesis. Kinases activate 
other enzyme proteins by adding phosphate from ATP, 
and cascades of kinases act as the most important cellular 
signaling pathways central to the regulation of critical cel-
lular functions such as growth, apoptosis, attachment, and 
angiogenesis. Malignant cells characteristically exhibit 
derangements of these controls due to mutations resulting 
in constitutive activation of one or more pathways, com-
pounded by evolving progression resulting from genomic 
instability (Hanagan and Weinberg 2000). The human 
genome codes for over 500 kinases including over 50 RTKs 
(Manning et al 2002) that are of major interest as targets 
for pharmaceutical attack. The RTKs are present at the cell 
surface and are the initial members of signaling cascades 
that respond to extracellular ligands secreted by other cells 
or by the same cell (autocrine action). An RTK consists of 
an extracellular receptor domain, hydrophobic membrane 
anchor, and intracellular catalytic site and P-loop for the 
donor ATP. Ligand binding results in RTK dimerization that 
activates kinase function and the ensuing cascade, subject 
to complex regulatory controls.
In the late 1990s, the identiﬁ  cation of all human kinases 
was undertaken by Sugen Inc (South San Francisco). This 
effort resulted in the publication of the essentially complete 
human “kinome” (Manning et al 2002). Sugen also explored 
the identiﬁ  cation of inhibitors of RTKs, by synthesizing small 
candidate molecules that compete for the catalytic site of the 
RTK(s) of interest. Initial clinical results with compounds 
SU6668 and SU5416 were disappointing because of poor 
pharmacologic properties and/or too narrow RTK speciﬁ  c-
ity (Stadler 2007a). A further series of 13 analogues were 
synthesized and of these, SU11248, now called sunitinib, 
had the most promising characteristics (Sun et al 2003). Spe-
ciﬁ  cally SU11248 had the best pharmacologic and binding 
potency proﬁ  le for VEGFR and PDGFR at the biochemical 
and cellular levels. In 2003, the Sugen parent company 
Pharmacia was acquired by Pﬁ  zer, and Sugen was disbanded 
(Garber 2003). Pﬁ  zer obtained patent rights to the Sugen 
compounds including SU11248 (sunitinib), a compound that 
was conﬁ  rmed in preclinical models as active against tumor 
cell VEGFR and PDGFR (Abrams et al 2003; Mendel et al 
2003), as well as endothelial cells and angiogenesis (Osusky 
et al 2004). Additionally, sunitinib inhibits KIT, a kinase 
constitutively activated in the majority of gastrointestinal 
stromal tumors (GIST). A randomized placebo-controlled 
trial as second-line therapy for GIST showed that sunitinib 
improved progression-free and overall survival (Demetri et al 
2006), resulting in regulatory approval for this indication. 
This trial is also the best source of information on the side-
effects of sunitinib compared to placebo.
Renal cell cancer
Renal cell cancer (RCC) is not a single entity as has long 
been recognized from light microscopy. About 85% of 
renal cell cancers are of predominantly clear cell type. 
Recent molecular analysis (Linehan et al 2005) has shown 
clear cell renal cancer to be the only type that has the VHL 
defect that creates the deﬁ  ned target for sunitinib. Follow-
ing the introduction of survival-prolonging therapies for the 
commonest metastatic cancers, RCC remained essentially 
refractory to drug therapy. Cytotoxic chemotherapy for 
RCC was largely abandoned following the realization that 
occasional “responses” are likely spontaneous remissions 
seen in untreated patients (Oliver et al 1989; Gleave et al 
1998), an observation that also spawned interest in immu-
notherapy, the main systemic therapy approach to RCC of 
the past two decades. In the USA, high dose interleukin-2 Biologics: Targets & Therapy 2008:2(1) 99
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(hdIL2) has been the only FDA-approved systemic treatment 
for RCC prior to the RTK inhibitors sunitinib and sorafenib. 
Because of severe toxicity, the applicability of hdIL2 has 
been limited to the ﬁ  ttest patients treated in specialized 
centers, and furthermore did not yield better median overall 
survival than interferon alfa (McDermott et al 2005) though a 
small percentage of patients have achieved durable complete 
remissions with hdIL2 not seen with other therapies (Fyfe 
et al 1996). Interferon-alfa (IFNα) given by subcutaneous 
injection three times weekly has gradually become the de 
facto standard of care and clinical trial comparator (Motzer 
et al 2002; Mickisch 2003) because of its safety, home-
based convenience, and small survival beneﬁ  t in two large 
studies (MRC Renal Cancer Collaborators 1999; Pyrhonen 
et al 1999) and meta-analysis (Coppin et al 2004). However, 
IFNα causes substantial fatigue in most patients, and failed 
to demonstrate beneﬁ  t over placebo in a recent large study of 
advanced RCC patients with intermediate prognosis (Negrier 
et al 2005). More effective treatment for RCC has long been 
needed, but few could have predicted the recent explosion 
of interest in RCC therapy arising from the early results of 
targeted therapy. At the annual meeting of the American 
Society of Clinical Oncology (ASCO), the number of podium 
and poster presentations devoted to RCC has increased from 
12 in 2001 to 46 in 2007, including plenary presentations for 
the past 2 years.
Endpoints of targeted therapy
Ultimately the value of cancer drug therapy to the patient 
must be described in terms of the incremental gain in the 
quantity or quality of life at acceptable risk, toxicity and 
economic cost, when comparing standard and novel treat-
ment options. These parameters are more problematic trial 
endpoints than categorical all-or-none outcomes like stroke. 
The clinical course of RCC is so variable that single-arm stud-
ies cannot be used to estimate efﬁ  cacy though can provide 
encouragement for proceeding to randomized trials. The 
objective response rate and progression-free survival have 
been introduced as surrogate endpoints that have utility and 
convenience for comparison of trial arms but have arguable 
relationship to patient-centered endpoints. The situation is 
compounded with studies of targeted cancer agents some of 
which may be cytostatic rather than cytoreductive, and new 
methodologies are required to evaluate the clinical meaning 
of disease stabilization (Ratain and Eckhardt 2004). These 
methods include the following: sequential measures of tumor 
burden in each patient colloquially called spidergrams (Elaraj 
et al 2004); histograms of percentage changes in tumor 
burden less than the conventional 50% sometimes referred 
to as waterfall plots (Ratain et al 2006); and randomized 
discontinuation of therapy for patients with stable disease 
after an initial phase of treatment (Stadler 2007b). However, 
as will be seen, sunitinib is more than cytostatic so that these 
issues are less important for sunitinib evaluation than some 
other targeted agents.
Prognostic factors have been well deﬁ  ned in both ﬁ  rst-
line (Motzer et al 2002) and second-line settings (Motzer 
et al 2004) and have been used to create pre-deﬁ  ned strata 
in pivotal phase III studies. These factors were identiﬁ  ed by 
retrospective review of patients entered on clinical trials. 
With ﬁ  rst-line interferon-alfa, short overall and progres-
sion-free survival outcome was associated with impaired 
performance status, low hemoglobin, high corrected serum 
calcium, disease-free interval of less than a year, and high 
lactate dehydrogenase. These factors were of equivalent 
import, and patients could be grouped into three categories: 
favorable risk (zero risk factors present at start of ﬁ  rst-line 
systemic therapy, median survival 30 months), intermediate 
risk (one or two risk factors, median survival 14 months), 
or poor risk (3 or more risk factors, median survival 5 
months) (Motzer et al 2002). In the second-line setting after 
cytokine failure, survival was similarly correlated with the 
ﬁ  rst three of the above factors, yielding 3 prognostic strata 
with median overall survivals of 22, 11.9, and 5.4 months 
(Motzer et al 2004).
Sunitinib phase I study and clinical 
pharmacology
One major phase I dose-escalation study of oral sunitinib 
in solid tumors has been reported (Faivre et al 2006), and 
between June 2001 and September 2003 accrued twenty-seven 
patients evaluable for toxicity of at least one course of 
therapy. A schedule of 4 weeks of sunitinib followed by a 
2-week rest period was used at the request of the regulatory 
authorities to allow recovery from possible bone marrow 
and adrenal toxicity seen in animal testing. Dosing was 
based on body surface area; however data were reported on 
a ﬁ  xed dose basis because this method resulted in negligible 
increase in the wide interpatient pharmacologic variability 
and because only 25 mg dose increments were available 
at that time. Dose-limiting toxicity was observed at step 
3, 75 mg po daily, with asthenia, hypertension, and throm-
bocytopenia probably secondary to microangiopathy (Faivre 
et al 2006). Additional toxicities were organ perforation or 
hemorrhage secondary to tumor necrosis, as well as cutaneous 
toxicity with bullous edema and splinter nail hemorrhages. Biologics: Targets & Therapy 2008:2(1) 100
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Hair depigmentation was also seen, a known marker of 
KIT inhibition (Moss et al 2003). Remarkably for a study 
of this type, four partial remissions and two near-complete 
remissions were observed in 13 evaluable patients treated 
at  75 mg/dose, and were associated with decreased tumor 
vascularity after one week of therapy as assessed by Dop-
pler ultrasound. However no remissions were seen in the 9 
patients receiving 50 mg/dose suggesting a potential dose-
response effect also seen in preclinical models and in a recent 
retrospective exposure-response analysis (Houk et al 2007). 
Nevertheless 50 mg daily (4 weeks on, 2 off) was considered 
the maximum tolerated dose to go forward to phase II trial 
and remains standard.
Oral sunitinib malate is metabolized by cytochrome 
CYP3A4 into an active desethyl metabolite SU12662, 
with potential for clinically relevant drug interactions. The 
combined blood levels of these two equipotent agents had 
a half-life of 2–3 days. Radiolabeled sunitinib is primarily 
excreted in the bile with minor urinary excretion as well. 
Limited data are available for patients with renal or hepatic 
dysfunction but sunitinib pharmacokinetics were unchanged 
in patients with mild or moderate hepatic impairment (Bello 
et al 2006).
Phase II single arm studies 
of sunitinib for renal cell cancer
Two studies examined the activity of sunitinib in patients 
with metastatic renal cell carcinoma previously treated with 
cytokine therapy. The schedule was again 4 weeks on, 2 
weeks off as used in phase I, at the phase I determined maxi-
mum tolerated dose of sunitinib 50 mg po daily. The ﬁ  rst 
phase II trial accrued 63 patients with any renal cancer histol-
ogy between January and July 2003 in a single center setting 
(Motzer et al 2006a). The primary endpoint was the objective 
response rate by the RECIST (Response Evaluation Criteria 
in Solid Tumors) method (Therasse et al 2000). Patients were 
treated until disease progression, unacceptable toxicity, or 
withdrawal of consent. Twenty-ﬁ  ve patients (40%) achieved 
a partial remission, often with imaging changes consistent 
with tumor necrosis. Median time to disease progression for 
all 63 patients was 8.7 months. Fatigue was the dominant 
subjective toxicity (27% of patients experienced grade 2, 
and 11% grade 3). Serial questionnaires showed that fatigue 
usually reversed during each 2-week break from therapy. 
Additional toxicities of note included diarrhea, cytope-
nias, decline in cardiac ejection fraction (11 patients), and 
hyperlipasemia without clinical pancreatitis (15 patients). 
One third of the patients required dose reduction to manage 
subjective or laboratory toxicities, most to 37.5 mg/dose. 
Pharmacokinetic data demonstrated median daily trough 
levels within the range shown to inhibit RTKs in preclinical 
models. Measured plasma VEGF-A levels tended to increase 
and VEGFR2 levels to decrease with sunitinib therapy. These 
biomarkers may be useful predictors of beneﬁ  t.
A second study conﬁ  rmed the efﬁ  cacy of second-line 
sunitinib in a multicenter setting (Motzer et al 2006b). One 
hundred and six nephrectomized renal cancer patients with 
clear cell histology were accrued during 2004 after disease 
progression following cytokine therapy. Thirty-six patients 
(34%) had documented partial remissions as assessed by 
independent third-party review. Toxicities were similar to 
those previously described with the addition of hand-foot 
syndrome (15%) and mucositis (12%). A combined analysis 
of the two phase II studies reported an overall 42% investiga-
tor assessed remission rate, and the median progression-free 
survival for responders was 14.8 months (Motzer 2006b).
Phase II studies in renal cell cancer have not necessarily 
provided a reliable guide to phase III outcomes (Zia et al 
2005) or subsequent regulatory approval (Gofﬁ  n et al 2005), 
reasons including preferential selection of prevalent patients 
with indolent lung metastases for phase II. However, taken 
together, the two phase II studies of second-line sunitinib 
demonstrated a striking remission rate similar to or greater 
than seen in ﬁ  rst-line phase II studies of the current standard 
comparator interferon-alfa, greatly exceeding the anticipated 
cytostatic drug action. It was therefore appropriate to pro-
ceed directly to a head-to-head comparison of sunitinib with 
interferon-alfa in a ﬁ  rst-line setting.
Phase III randomized study 
of sunitinib for renal cell cancer
A pivotal randomized phase III study of ﬁ  rst-line sunitinib 
versus interferon-alfa has been reported in detail (Motzer et al 
2007a) and recently updated (Motzer et al 2007b). Eligibility 
requirements included measurable metastatic renal cell cancer 
of clear-cell subtype, performance status 0–1, and no prior 
systemic therapy. Patients with brain metastases, uncontrolled 
hypertension, or recent cardiovascular events were excluded. 
Eligible consenting patients were randomly assigned to 
receive either sunitinib 50 mg orally for 4 weeks of each 6-
week cycle, or interferon alfa-2a (Roche) at a conventional 
dose of 9 MU 3 times per week by subcutaneous injection. The 
primary endpoint was progression-free survival as assessed 
by third party blinded central review of imaging studies 
performed every cycle for the ﬁ  rst four cycles and alternate 
cycles thereafter. The study was designed to detect a 1.5 month Biologics: Targets & Therapy 2008:2(1) 101
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improvement in the primary endpoint at a signiﬁ  cance level 
of 0.05 and 90% power, requiring 471 events.
Seven hundred ﬁ  fty patients were enrolled from 101 
centers on 5 continents. Fifteen of 375 interferon-assigned 
patients withdrew consent without therapy but were included 
in the analysis. Accrual was completed October 2005. In 
November 2005, a second pre-planned interim analysis was 
performed and, with input from the independent data and 
safety monitoring committee, patients on the interferon alfa 
arm with disease progression were allowed to cross over to 
receive sunitinib. As of February 2007, only 6% of inter-
feron-assigned patients had crossed to sunitinib (Motzer et al 
2007b). Toxicity was as expected for the two agents, with 
fatigue seen in patients on both arms but was more severe 
with interferon alfa, whereas diarrhea, hypertension, and 
hand-foot syndrome occurred predominantly with sunitinib. 
Similar proportions of patients on sunitinib or interferon alfa 
required treatment delays, dose reductions, or discontinued 
therapy for adverse events.
Independently assessed progression-free survival, the 
primary endpoint, was substantially better with sunitinib than 
interferon alfa (Figure 1). As of February 2007 (Motzer et al 
2007b), the updated median progression-free survival was 
11.0 months for sunitinib versus 5.1 months for interferon 
alfa, hazard ratio 0.54 (95% CI 0.44–0.66; p   10−6). Multi-
variate analysis of the sunitinib arm found that diagnosis to 
treatment interval of less than a year, reduced patient perfor-
mance status, and corrected serum calcium  10 mg/dL were 
independent predictors of worse progression-free survival 
(Motzer et al 2007b).
The independently assessed proportion of patients achiev-
ing a major tumor remission was 39% for sunitinib compared 
with 8% for interferon alfa (p   10−6), though no conﬁ  rmed 
complete responses were seen. The interferon alfa outcomes 
are consistent with previous phase III studies (Coppin et al 
2004). Importantly for treatments with substantial toxicity, 
patient-reported quality-of-life scores were statistically 
superior (p   0.001) for sunitinib to a clinically meaningful 
degree using validated general and kidney cancer quality-of-
life instruments (Motzer et al 2007a, on-line appendix).
Overall survival, a secondary study outcome, is too 
early to fully report (Motzer et al 2007b). Early overall 
survival at the time of the second interim analysis with 
85% of patients still alive was better on the sunitinib arm, 
hazard ratio for death was 0.65, p = 0.02, but this did not 
reach the pre-speciﬁ  ed level for statistical signiﬁ  cance for 
an interim analysis (Motzer et al 2007a). Thus far, 20 of 
319 patients have been crossed over from interferon alfa 
to sunitinib following disease progression or withdrawal 
for an adverse event (Motzer et al 2007b). This crossover 
will dilute any potential overall survival difference and 
make it more difﬁ  cult to achieve statistical signiﬁ  cance 
or to estimate any quantitative survival gain attributable 
to sunitinib.
Indirect comparison of sunitinib 
with other targeted therapies
Randomized trials that directly compare sunitinib with other 
targeted agents have not been reported. A systematic review 
of this rapidly changing ﬁ  eld has been completed (Coppin 
et al 2008). Cautious indirect comparisons may be made by 
inspection of randomized trials of ﬁ  rst-line interferon alfa 
versus agents other than sunitinib.
Sorafenib (Nexavar®, Bayer), like sunitinib, is a small 
molecule multitargeted receptor tyrosine kinase inhibitor 
directed against angiogenesis and additional targets including 
raf kinase. One study randomized 189 systemically untreated 
patients to receive either oral sorafenib 400 mg twice daily 
or subcutaneous interferon alfa 9 MU three times weekly 
(Szczylik et al 2007). Progression-free survival was not 
improved over interferon but the power to detect a difference 
was limited by the small size of this phase II trial. Addition-
ally, sorafenib was tested well below the maximum dose of 
1200–1600 mg twice daily tolerated by over 90% of patients 
(Amato et al 207) and further evaluation of sorafenib at the 
escalated dose of 600 mg twice daily or more is in progress 
(Szczylik et al 2007).
Temsirolimus (CCI-779, Torisel®,Wyeth), an inhibitor 
of the mammalian target of rapamycin, has been compared 
with interferon-alfa in a phase III trial of 626 systemically 
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untreated patients with advanced renal cancer (Hudes et al 
2007). Eligibility was conﬁ  ned to patients with at least 
three of six factors predictive of short survival (including 
multi-organ involvement), this endpoint therefore being 
rapidly reached for reporting purposes. Overall survival, the 
primary study endpoint, was improved with temsirolimus 
(hazard ratio for death 0.73; p = 0.008) with median sur-
vival 10.9 months compared with 7.3 months for interferon 
alfa. Response rates were low in this adverse patient group. 
Median progression-free survival was approximately 2 
months longer for temsirolimus versus interferon alfa, hazard 
ratio not reported. A pre-planned subset analysis suggests that 
the survival beneﬁ  t of temsirolimus over interferon extends to 
patients with non-clear histologies (Dutcher et al 2007) that 
have been excluded from other pivotal trials (Escudier et al 
2007; Motzer et al 2007). For patients with poor prognostic 
features including short disease-free interval, multiple organ 
involvement, or adverse laboratory ﬁ  ndings, temsirolimus 
may be superior to sunitinib based on indirect comparison 
of outcomes; temsirolimus was approved by the US FDA 
in May 2007. High dose interleukin-2 is another option for 
this subset (McDermott et al 2005) but high toxicity limits 
its availability.
Several randomized studies have examined the addition 
of agents to ﬁ  rst-line interferon alfa, and would become 
relevant to sunitinib if overall survival was superior in these 
studies to render interferon alfa alone an obsolete compara-
tor. The addition of interferon alfa to temsirolimus (Hudes 
et al 2007) or thalidomide (Gordon et al 2004) resulted in 
additional toxicity without improved patient survival. The 
addition of bevacizumab or placebo to interferon alfa has 
been examined in a recently presented phase III study dem-
onstrating improved progression-free survival (hazard ratio 
0.63, p   0.0001); mature survival results are awaited with 
interest (Escudier et al 2007b).
Cost-effectiveness of sunitinib 
as ﬁ  rst-line therapy
Having established that sunitinib provides better progres-
sion-free survival, quality-of-life, the convenience of oral 
therapy, and a favorable survival trend compared to inter-
feron-alfa, the question of cost in relation to quantitative 
beneﬁ  t must be addressed. In a medical environment where 
expensive new therapies are competing for limited ﬁ  nancial 
resources, guiding principles include recognition of the issue, 
transparent evaluation by parties with negligible conﬂ  ict of 
interest, and application of a standardized approach (Eddy 
1994) such as used by the National Centre for Excellence 
in the UK (www.nice.org.uk). The use of a ﬁ  xed cutoff 
such as $50–100,000 per life year, useful when only a small 
proportion of individuals would need chronic therapy such 
as hemodialysis, is no longer valid when the majority of 
patients with incurable cancer now have such options. The 
actual or imminent availability of targeted drugs for common 
malignancies and other conditions will only highlight the 
need for consistency and rigor rather than political advo-
cacy. Published analyses almost invariably have a favorable 
conclusion and sunitinib is no exception (Remak et al 2007); 
caution is advised especially in regards to assumptions and 
5- to 10-year projections of immature data. A safer approach 
is to use available ﬁ  rm data. For sunitinib, in the absence of 
an overall survival beneﬁ  t, cost per life year gained cannot 
be estimated and other arguments are required. The gain 
in progression-free expectancy, analytically equivalent to 
incremental gain in life expectancy, is given by the area 
between the progression-free curves of a randomized trial 
(Wright and Weinstein 1998): for sunitinib versus interferon 
alfa, this progression-free expectancy gain is approximately 
3 months (derived from Motzer et al 2007b). Based on such 
estimates of incremental beneﬁ  t and cost between competing 
options, each jurisdiction or individual must make their own 
decisions for available funds. In due course, a population-
based outcomes approach may also be useful for estimating 
sunitinib effectiveness, that is, survival impact in a real 
clinical setting (Kollmannsberger et al 2007).
Sunitinib in current clinical 
management of renal cancer: 
practical issues
Sunitinib was given accelerated approval by the US FDA in 
January 2006 (Goodman et al 2007) on the basis of improved 
surrogate endpoints reasonably likely to predict clinical 
beneﬁ  t, such as the subsequently demonstrated improvement 
in quality-of-life measures. Similarly, qualiﬁ  ed approval 
was issued by the European Medicines Evaluation Agency 
in April 2006, and by Health Canada in August 2006 “for 
the treatment of metastatic renal cell carcinoma of clear cell 
histology after failure of cytokine-based therapy or in patients 
who are considered likely to be intolerant of such therapy” 
(Health Canada Notice of Compliance with Conditions, 
August 17, 2006). Sunitinib is available (Sutent®, Pﬁ  zer) in 
12.5, 25, and 50 mg capsules.
Since these approvals, patients have been treated with 
sunitinib on expanded access programs providing experi-
ence from 52 countries (Gore et al 2007), the majority 
having received prior drug therapy therapy (cytokine 78%, Biologics: Targets & Therapy 2008:2(1) 103
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anti-angiogenic 7%). The eligibility criteria were much 
broader than the pivotal phase III trial, with unrestricted 
performance status and renal cell subtype, and asymptomatic 
brain metastases permitted. The standard regimen remains 
50 mg for 4 weeks of a 6-week cycle. Adverse events were 
as expected and in particular were no worse in patients of 
concern, ie, older, lower performance status or with brain 
metastases. Although the major remission rate of 9.3% 
was lower than that independently assessed in phase III 
for reasons possibly related to patient selection, remissions 
were seen in all subgroups. Many additional patients had 
prolonged stable disease or clinical improvement, endpoints 
of uncertain validity.
For poor prognosis patients with three or more adverse 
factors, a minority group with short median survival, tem-
sirolimus has been shown to give overall survival superior 
to interferon and may therefore be the preferred treatment 
option for this patient subset (Hudes et al 2007). For the 
majority of clear-cell renal cancer patients who have good 
or intermediate prognosis disease, sunitinib is becoming the 
commonly preferred ﬁ  rst-line drug (Atkins 2007) and has 
received Category 1 designation in the US NCCN guidelines 
for this indication (www.nccn.org accessed 2007/8/15); in 
Canada, the BC Cancer Agency has implemented a similar 
policy on a compassionate access basis (www.bccancer.
bc.ca accessed 2007/8/15). Sunitinib has some utility as 
second-line therapy, for example after ﬁ  rst-line bevacizumab 
(George et al 2007) but sorafenib has better documented 
beneﬁ  t after cytokine failure (Escudier et al 2007a). With the 
growing consensus and availability of sunitinib for selected 
patients with renal cancer, practical management issues 
are becoming increasingly important, in particular toxicity 
recognition and management. As with any cancer therapy, 
cost and toxicity considerations obligate the provider to 
monitor the extent of disease on a cycle-by-cycle basis and 
discontinue therapy at progression.
A summary of sunitinib toxicity management issues is 
provided in Table 1. Dose reductions from 50 mg daily to 37.5 
mg or occasionally to 25 mg were required in 28% and 9% 
respectively in the expanded access setting (Gore et al 2007). 
The 2-week break per cycle can assist toxicity attribution and 
recovery. Subjective toxicities can be patient-reported and 
managed symptomatically, with gastrointestinal or cutaneous 
symptoms being predominant. Pain at tumor sites may occur. 
Blood pressure must be monitored at least every 2 weeks for 
early cycles and appropriately managed (Chowdhury et al 
2006). CBC must be monitored each cycle for cytopenias, and 
TSH about every 3 months for detection of commonly seen 
hypothyroidism (Desai et al 2006). Left ventricular dysfunc-
tion may occur in at least 10% of patients and cardiac ejection 
fraction evaluation should be considered before and during 
sunitinib therapy especially for patients with prior cardiac 
history or current symptoms. Prolongation of the PR and QT 
interval has been described with sunitinib, so that baseline 
ECG should be considered and concomitant use of drugs 
prolonging these intervals avoided. Adrenal necrosis was seen 
in preclinical studies, and adrenal insufﬁ  ciency monitoring 
has been recommended in patients with stressors such as 
surgery, trauma, or severe infection (Goodman et al 2007). 
Because sunitinib is metabolized by cytochrome CYP3A4, 
strong inhibitors of this enzyme such as ketoconazole result 
in increased and potentially toxic blood levels of sunitinib and 
its active metabolite; conversely CYP3A4 inducers such as 
rifampin may reduce levels and efﬁ  cacy – such interactions 
should be considered, avoided where possible, or managed 
by sunitinib dose adjustment (Goodman et al 2007).
Conclusions and future directions
Sunitinib has followed the idealized paradigm from 
laboratory to clinic. A strong rationale for suppressing the 
angiogenesis pathway led to screening of candidate small 
molecules able to inhibit multiple tyrosine kinase receptors, 
with sunitinib (originally SU11248) selected for further 
testing. Anti-tumor activity was sequentially demonstrated 
in preclinical models, phase I studies, and in phase II and 
III trials in renal cell cancer and gastrointestinal stromal 
tumors, eventually achieving approval in North America 
and elsewhere for both tumor types (Goodman et al 2007). 
Efﬁ  cacy is well established for sunitinib as initial therapy for 
good-to-moderate prognosis patients with metastatic renal 
cell cancers and a majority clear cell component. Beneﬁ  ts in 
phase III trial include improved chance of remission (39% vs 
8%), longer progression-free status (hazard reduction 46%), 
and better quality-of-life than interferon-alfa, the previous 
standard in this patient population (Motzer et al 2007a). 
Table 1 Sunitinib toxicity monitoring checklist
Potential problem  Action required
Subjective toxicities  Self-reporting, symptom management
Anorexia, taste change  Weigh each cycle (6 weeks)
Hypertension  Measure and record every 2 weeks
Cytopenias  Complete blood count each cycle
Hypothyroidism  TSH baseline and 3-monthly
Cardiac history or symptoms  ECG, cardiac ejection fraction
Tumor breakthrough weeks off  Consider continuous 37.5 mg/day
Disease progression  Measure disease each cycle initiallyBiologics: Targets & Therapy 2008:2(1) 104
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In an expanded access setting, the major response rate was 
only 9% but applied to a broad patient population (Gore et al 
2007) and can be achieved with adequate safety provided that 
attention is paid to detection and management of potentially 
asymptomatic toxicities. Although sunitinib was approved in 
2006 for second-line use after cytokines, it is currently less 
well validated than sorafenib for which phase III data is now 
available (Escudier et al 2007a).
Many additional questions must now be addressed by 
appropriate clinical trials. Biomarkers may help patient 
selection for different targeted agents. Early detection of 
response to sunitinib and similar agents by functional imag-
ing techniques or biomarker measurement may permit earlier 
recognition of non-responsive cancers. Improved efﬁ  cacy of 
sunitinib is needed and may come from continuous rather 
than interrupted scheduling (Srinivas et al 2007); this is being 
tested in a phase III trial. The addition to sunitinib of other 
agents such as interferon-alfa or a variety of other targeted 
agents is being actively explored in current generation trials. 
Optimal sequencing of cytokines and targeted agents needs 
much clariﬁ  cation. Approaches that can delay or avoid the 
emergence of sunitinib-resistant disease are needed, most 
likely by targeting multiple different signaling pathways 
(Vogelzang and Sternberg 2007). In patients with the primary 
still in situ at the start of therapy for advanced disease, the 
role of nephrectomy before or after sunitinib is currently 
unclear (Rini and Campbell 2007). After sunitinib, second-
line temsirolimus versus sorafenib is being examined in a 
multicenter North American randomized trial.
Finally, sunitinib is starting to be tested in the adjuvant 
setting after nephrectomy in patients at high risk of relapse 
from micrometastases, a situation where no established 
adjuvant therapy currently exists. An intergroup study led 
by the Eastern Co-Operative Oncology Group will compare 
adjuvant sunitinib with sorafenib and placebo in over 1300 
high-risk patients following nephrectomy. The primary 
endpoint is disease-free survival, an outcome that will be 
reached in a reasonable timeframe and will avoid the issue of 
crossover by placebo-assigned patients at relapse. However 
improved overall survival would be needed to demonstrate 
that it is better to use an anti-angiogenesis agent early, rather 
than later when the toxicity and cost impinge only on those 
destined to relapse.
There is no doubt that the next several years will see 
much further progress in our understanding and management 
of renal cancer with sunitinib and other targeted agents, an 
exciting prospect for a condition that was, until recently, 
dismal to have and to treat.
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